急性冠脉综合征患者PCI术后应用国产硫酸氢氯吡格雷的疗效

比较急性冠脉综合征（ACS）患者择期PCI术后国产氯吡格雷（泰嘉,Talcom）和进口氯吡格雷（波立维,Plavix）应用的有效性和安全性。方法：158例行择期PCI的ACS患者随机分为：国产氯吡格雷组和进口氯吡格雷组,各79例。随访12个月以上,观察两组术后不良心血管事件及药物不良反应情况。结果：进口氯吡格雷组心源性死亡1例、非致死性心肌梗死1例、靶血管再次血运重建1例、脑卒中1例。国产氯吡格雷组心源性死亡0例、非致死性心肌梗死1例、靶血管再次血运重建2例、脑卒中1例。两组心血管不良事件发生率无显著差异（5.06%比5.06%,P〉0.05）。药物不良反应：进口氯吡格雷组胃肠道反应5例、出血1例、血小板减少1例。国产氯吡格雷组胃肠道反应7例、出血1例、血小板减少2例,两组不良反应发生率无显著差异（8.86%比12.66%,P〉0.05）。结论：与进口氯吡格雷相比,国产氯吡格雷应用于PCI术后患者是安全、有效的。

Curative effect of domestic clopidogrel bisulfate on patients with acute coronary syndrome after PCI

Objective：To compare validity and safety between domestic clopidogrel（Talcom）and imported clopidogrel（Plavix）in patients with acute coronary syndrome（ACS）after selective percutaneous coronary intervention（PCI）.Methods：A total of 158ACS patients undergoing selective PCI were randomly and equally divided into domestic clopidogrel group and imported clopidogrel group.Both groups were followed up over 12months,and adverse cardiovascular events and adverse drug reactions after PCI were observed in two groups.Results：There was one case with cardiogenic death,one case with non-fatal myocardial infarction,one case with target vessel revascularization and one case with cerebral stroke in imported clopidogrel group.There was none with cardiogenic death,one case with non-fatal myocardial infarction,two cases with target vessel revascularization and one case with cerebral stroke in domestic clopidogrel group.There was no significant difference in incidence rates of adverse cardiovascular events（5.06% vs.5.06%,P＆gt;0.05）between two groups.There were five cases with gastrointestinal reactions,one case with bleeding and one case with thrombocytopenia in imported clopidogrel group.There were seven cases with gastrointestinal reactions,one case with bleeding and two cases with thrombocytopenia in domestic clopidogrel group.There was no significant difference in incidence rates of adverse drug reactions between two groups（8.86% vs.12.66%,P＆gt;0.05）.Conclusion：Compared with imported clopidogrel,application of domestic clopidogrel is safe and effective in patients after percutaneous coronary intervention.